Center Laboratories, Inc. Stock

Equities

4123

TW0004123005

Pharmaceuticals

End-of-day quote Taipei Exchange 06:00:00 2024-05-20 pm EDT 5-day change 1st Jan Change
45.75 TWD -0.54% Intraday chart for Center Laboratories, Inc. +0.77% +3.27%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2022 768M 23.8M Sales 2023 1.39B 43.21M Capitalization 30.63B 949M
Net income 2022 102M 3.16M Net income 2023 -995M -30.84M EV / Sales 2022 38.1 x
Net Debt 2022 1.12B 34.73M Net Debt 2023 2.2B 68.12M EV / Sales 2023 23.5 x
P/E ratio 2022
278 x
P/E ratio 2023
-29.5 x
Employees -
Yield 2022
2.1%
Yield 2023
3.39%
Free-Float 74.37%
More Fundamentals * Assessed data
Dynamic Chart
Center Laboratories, Inc. Announces the Resignation of Lin Shirley Yi-Hsien as Independent Director and Member of Audit Committee and Remuneration Committee CI
Center Laboratories, Inc. cancelled the transaction announced on June 20, 2023 CI
Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mycenax Biotech Inc. announced that it expects to receive funding from Center Laboratories, Inc., JCR Pharmaceuticals Co., Ltd., Taiwan BioVenture Company, Jason Technologies Ltd CI
Center Laboratories, Inc. Announces Wang, Su-Chi Holds Concurrent Position as Chief Investment Officer and Chief Operating Officer CI
Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2022, Payable on October 13, 2023 CI
Center Laboratories, Inc. announced a financing transaction CI
Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Center Laboratories, Inc. Proposes Cash Dividend for the Period from January 1, 2022 to December 31, 2022 CI
Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Center Laboratories, Inc. Announces Executive Appointments CI
Center Laboratories, Inc. Announces Management Changes CI
Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
More news
1 day-0.54%
1 week+0.77%
Current month+5.29%
1 month+8.93%
3 months-0.87%
6 months+3.27%
Current year+3.27%
More quotes
1 week
44.75
Extreme 44.75
46.40
1 month
42.90
Extreme 42.9
46.70
Current year
41.35
Extreme 41.35
49.25
1 year
40.80
Extreme 40.8
61.77
3 years
38.57
Extreme 38.5746
61.77
5 years
22.05
Extreme 22.0524
67.47
10 years
22.05
Extreme 22.0524
67.47
More quotes
Managers TitleAgeSince
Chief Executive Officer - 98-08-02
Director of Finance/CFO - 22-12-07
Chairman - 00-07-31
Members of the board TitleAgeSince
Chairman - 00-07-31
Director/Board Member 74 22-05-19
Director/Board Member - 10-06-13
More insiders
Date Price Change Volume
24-05-21 45.75 -0.54% 1,470,039
24-05-20 46 0.00% 1,718,133
24-05-17 46 +2.45% 2,140,615
24-05-16 44.9 +0.34% 1,830,415
24-05-15 44.75 -1.43% 2,214,583

End-of-day quote Taipei Exchange, May 20, 2024

More quotes
Center Laboratories, Inc. is a Taiwan-based company principally engaged in the production, marketing and distribution of infant nutrition products, as well as the research and development, processing, production, packaging, marketing and sales of dairy products. The Company's main products include dairy products and probiotic products. The Company is also involved in the manufacture, wholesale and retail of western medicines. The Company distributes its products in the domestic market and to overseas markets.
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW